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   Prostatic acid phosphatase （PAPase） activities were determined by double antibody radioim－
munoassqy developed by Eiken Co．’@in 18 patients with untreated prostate cancer， 19 patients with
prostate cancer under treatlnent， 80 patients with benign prestatic hypertrophy， 15 patients with
cancer of the other orgaps （3 patients with renal cell cancer， 5 patients with bladder cancer and 7
品目tients with liepatic cancer） and normal male and female subjects．
    Ivlean PAPase values were 2．45±1．78 ng／ml in 8 patients with． untreated prostate cancer at stages
Ti and T2’C 25．41±22．49 ng／ml in 10 patients with untreated prostate cancer．at．stages T3 and T4， 1．03
土0．57ng／ml in 8 patients with prostate cancer at stages TI and T2 under trcatment，826土12．33
ng／ml in．llpatients with prostate・cancer at stages T3狐d T4 under treatm6nt，1，．67土L27ng／ml in
80 patients with benign prostatic hypertrophy， 1．38±O．48 ng／ml in 15 patients with cancer of the
other organs and 1．44±0．60 ng／血i in 16 normal male and female su切ects．
    PAPase values were significantly higher in patients with prostate cancer at stages T3 and T4 than
those in the other groups． Furthermore， PAPase values were significantly higher in patients with
prostate cancer at stage Ti and T2’than those．in patients with benign prostatic hypertrophy， patients
with cancer of／the other organs and normal male and female subjects．
   When 3 ngfrn1 was regarded as the upper limit of normal PAPase， 2 out of the 8 patients with
prostate cancer at stages Ti and T2， and 7 odt of the 10 patients with prostate cancer at stages T3 and
T4 showed ’a positive reaction． ． False posltive results were seen in none of the pat’ients with cancer of
the other organs and．in none．of the normal male and femaJe subjects， but were seen in 7 out of the
80 patients with benign prostatic hypertrophy．
    In addition， PAPase values were determined by radioimmunoassay in 166 males over 50－years－old
of whom serum specimens were obtained by the resident health examination in S village．
   From the results obtained， determination of PAPase by radioimmunoassay was considered usefuI
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 前立腺癌とacid phosphataseとの関係は， Gutman
らによりはじめて検討され，その後Hugginsと
Hodges ”t）は骨転移を認めている前立腺癌患者の70％
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Table 2．S村におけるスクリーニングテストの結果
   PAP濃度No，   ng／ml
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は2，45±L73 ng／ml， stage T3，．T4群10例のそれは，
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                ミ       症状により適宜増減。
       慢性肝疾患には，1日1図，40m 1を静脈内に注射。
       年齢，症状により適宜増減。
                  包装 20ml 5管・30管，5ml 5管・50管，2m110管・100管
                       ※使用上の注意は，製品の添付文書をご参照下さい。
健保適用
    ●内服療法には』曜盟昏回7；錠二号
                         包装 iOOO錠，5000錠
麟難ミノファーゲン製薬本舗（〒160）東京都新宿区四谷3－2－7，
